Does osimertinib treatment discriminate young patients?

Abstract

Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1 st generation EGFR-TKI treatment. Beyond T790M mutation, osimertinib also selectively and irreversibly inhibits EGFR harboring the common “sensitive” mutations such as 19del and L858R.